• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,070.84 567.99
( 0.75%)
Global Indices
Nasdaq
46,970.79 391.31
(0.84%)
Dow Jones
6,721.52 68.33
(1.03%)
Hang Seng
53,528.27 -222.88
(-0.41%)
Nikkei 225
10,406.71 89.02
(0.86%)
Forex
USD-INR
92.32 0.03
(0.03%)
EUR-INR
105.40 -1.04
(-0.98%)
GBP-INR
122.05 -1.31
(-1.06%)
JPY-INR
0.58 0.00
(-0.37%)

EQUITY - MARKET SCREENER

Hindusthan Urban Infrastructure Ltd
Industry :  Electric Equipment
BSE Code
ISIN Demat
Book Value()
539984
INE799B01025
557.0592043
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
0
280.17
EPS(TTM)
Face Value()
Div & Yield %
0
2
0
 

Aurobindo Pharma arm receives 4 observations after US FDA inspection
Feb 28,2026
The facility (Unit-I), located at Kolthur Village, Shameerpet Mandal, Ranga Reddy, Telangana, was inspected from 16 February to 27 February 2026, and the inspection concluded with four observations. The company said it will respond to the US FDA within the stipulated timelines.

The company confirmed there is no impact on its financials or operations due to the inspection. Aurobindo Pharma stated its commitment to maintaining high-quality manufacturing standards across all its facilities worldwide and said it will update the stock exchanges if there is any further information.

Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.

The company’s consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25.

Shares of Aurobindo Pharma shed 0.04% to end at Rs 1,221.55 on the BSE on Friday.